Century TherapeuticsIPSC -3.75%46 PB Ratio is 1.57 as of Jul. 08, 2026, which is 109% above its 10-year median of 0.75. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.91 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,225 Biotechnology companies, Century Therapeutics ranks better than 71.51% on this metric.
Century Therapeutics Inc stock PB Ratio (=1.63) is close to 3-year high of 1.71.
The historical rank and industry rank for Century Therapeutics's PB Ratio or its related term are showing as below:
IPSC'
s PB Ratio Range Over the Past 10 Years
Min: 0.16 Med: 0.75 Max: 1.96
Current: 1.57
During the past 7 years, Century Therapeutics's highest PB Ratio was 1.96. The lowest was 0.16. And the median was 0.75.
IPSC's PB Ratio is ranked better than 71.51% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs IPSC: 1.57
During the past 12 months, Century Therapeutics's average Book Value Per Share Growth Rate was -47.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.50% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Century Therapeutics was -29.50% per year. The lowest was -36.10% per year. And the median was -32.80% per year.
Back to Basics: PB Ratio
Century Therapeutics (NAS:IPSC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Century Therapeutics PB Ratio Related Terms
Century Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Century Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Century Therapeutics (IPSC) has a PB Ratio of 1.57 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Century Therapeutics and its competitors. This is 109% above median its historical median of 0.75. Over the past decade, Century Therapeutics' PB Ratio has ranged from 0.16 to 1.96. According to the industry distribution chart, Century Therapeutics ranks #349 out of 1225 companies in the Biotechnology industry, placing it in the top 28.5%.
Is Century Therapeutics' PB Ratio too high?
Century Therapeutics' current PB Ratio of 1.57 is 109% above median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 1.96. The Biotechnology industry median PB Ratio is 2.92. Century Therapeutics' value of 1.57 is 46.2% below this industry median. Based on the distribution chart, Century Therapeutics ranks #349 out of 1225 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' PB Ratio compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #349 out of 1225 companies for PB Ratio. This puts Century Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.92. Century Therapeutics' value of 1.57 is 46.2% below this benchmark. Historically, Century Therapeutics' own PB Ratio has ranged from 0.16 to 1.96 over the past decade. While the company's 10-year median is 0.75 vs. the industry median of 2.92, Century Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Century Therapeutics's current PB Ratio of 1.57 is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Century Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Century Therapeutics's current PB Ratio is 1.57, which is 109% above median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.32 — trading 94.1% below its estimated fair value. The current PB Ratio is 1.57, which is 109% above median its 10-year median of 0.75 and 46.2% below the Biotechnology industry median of 2.92. Century Therapeutics' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current PB Ratio is 1.57 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.32 is trading 94.1% below its estimated GF Value™ of $38.91.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
PB Ratio: 1.57 (109% above median its 10-year median of 0.75)
GF Value™: $38.91 vs. price of $2.32 (94.1% below fair value)
Industry Position: 46.2% below the Biotechnology median (#349 of 1225)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
